A 2-year HRQL Observational Study Evaluating the Effect of Treatment With Adalimumab on Work Productivity and Sleep in Patients With Rheumatic Diseases in Greece
Phase of Trial: Phase IV
Latest Information Update: 16 Nov 2015
At a glance
- Drugs Adalimumab (Primary)
- Indications Ankylosing spondylitis; Psoriatic arthritis; Rheumatoid arthritis
- Focus Therapeutic Use
- Sponsors Abbott Laboratories; AbbVie
- 10 Jun 2017 Biomarkers information updated
- 31 Jul 2014 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 08 Jul 2013 Planned end date changed from 1 Jul 2015 to 1 Jul 2014 as reported by ClinicalTrials.gov.